Literature DB >> 28233

Climbing behaviour induced by apomorphine in mice: a potential model for the detection of neuroleptic activity.

B Costall, R J Naylor, V Nohria.   

Abstract

Apomorphine and the putative dopamine agonist, 2-(N, N-dipropyl)-amino-5, 6-dihydroxytetralin induced dose-dependent climbing behaviour in the mouse which was measured in wire mesh lined cages as the percentage of time spent climbing in the 30 min period following the first climb and as the maximum time spent in a single climb throughout the drug effect. These These two measures were generally found to parallel excepting when the interacting agent caused muscular hypotonia. All potential interacting agents were given as pretreatments to determine changes in motor function which may interfere with the climbing induced by 1.0 mg/kg s.c. apomorphine. The possibility of a change in the apomorphine response to a sterotyped biting, which would also interfere with climbing, was also considered. Excluding these non-specific changes, climbing behaviour was shown to be antagonised, dose-dependently, by low doses of typical and atypical neuroleptic agents (haloperidol, fluphenazine, loxapine, pimozide, oxiperomide, clozapin, thioridazine, sulpiride, tiapride and metoclopramide) but not specifically by other psychoactive agents. Climbing behaviour was modified by serotonergic agents; the agonist quipazine reduced or abolished, whilst the antagonists, methysergide and cyproheptadine, enhanced the response. Picrotoxin specifically reduced climbing behaviour but sodium valproate exerted non-specific effects, precluding conclusions as to a GABA involvement. Cholinergic and noradrenergic involvements with climbing were also apparently eliminated by the ineffectiveness of atropine, aceperone, piperoxan and propranolol. The involvement of serotonin with climbing was extended to the actions of the neuroleptics: the antagonistic effects of typical neuroleptics (haloperidol, fluphenazine, loxapine) were markedly enhanced by combination with methysergide or cyproheptadine whilst the effects of clozapine, sulpiride and thioridazine were significantly reduced. The actions of metoclopramide, oxiperomide, pimozide and tiapride were not generally modified by such combinations. These differences are discussed in terms of differential abilities to induce extrapyramidal disturbances and the mouse climbing model is forwarded as a test with potential to detect antipsychotic agents of different activity spectra.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 28233     DOI: 10.1016/0014-2999(78)90251-0

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  22 in total

1.  Typical and atypical neuroleptics antagonize MK-801-induced locomotion and stereotypy in rats.

Authors:  D C Hoffman
Journal:  J Neural Transm Gen Sect       Date:  1992

2.  Dopamine neurochemical profile of atypical antipsychotics resembles that of D-1 antagonists.

Authors:  C A Altar; W C Boyar; A Wasley; S C Gerhardt; J M Liebman; P L Wood
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-08       Impact factor: 3.000

3.  Evaluation of the antipsychotic potential of aqueous fraction of Securinega virosa root bark extract in mice.

Authors:  M G Magaji; M Mohammed; R A Magaji; A M Musa; I Abdu-Aguye; I M Hussaini
Journal:  Metab Brain Dis       Date:  2014-01-22       Impact factor: 3.584

4.  Neurobehavioural evaluation of resveratrol in murine models of anxiety and schizophrenia.

Authors:  Mohammed Garba Magaji; Loretta Oghenekome Iniaghe; Mutiat Abolarin; Opeyemi Isa Abdullahi; Rabiu Abdusalam Magaji
Journal:  Metab Brain Dis       Date:  2016-11-22       Impact factor: 3.584

5.  On the importance of mesolimbic mechanisms for the control of apomorphine induced climbing behaviour in the mouse [proceedings].

Authors:  B Costall; R J Naylor; V Nohria
Journal:  Br J Pharmacol       Date:  1980-01       Impact factor: 8.739

6.  Rat climbing behavior elicited by stimulation of cerebral dopamine receptors.

Authors:  P Protais; J J Bonnet; J Costentin; J C Schwartz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-02       Impact factor: 3.000

7.  Unexpected potentiation by discriminant benzamide derivatives of stereotyped behaviours elicited by dopamine agonists in mice.

Authors:  M Vasse; P Protais; J Costentin; J C Schwartz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-04       Impact factor: 3.000

8.  Effects of three dopamine agonists on cage climbing behavior.

Authors:  G Gianutsos; J L Palmeri
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

9.  Dopamine agonist action in mesolimbic, cortical and extrapyramidal areas to modify spontaneous climbing behaviour of the mouse.

Authors:  B Costall; J F Eniojukan; R J Naylor
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

10.  Use of the intracerebral injection technique to elucidate mechanisms of apomorphine climbing and its antagonism in the mouse.

Authors:  B Costall; R J Naylor; V Nohria
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.